Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Vaccinations

Vaccinations

Diphtheria

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...

Arboviral Encephalitis

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026

Same author

Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.

Nature medicine·2026

Same author

Corrigendum to 'Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome' Journal of Investigative Dermatology Volume 145, Issue 8, August 2025, Pages 2021-2033.e3.

The Journal of investigative dermatology·2026

Same author

Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.

The New England journal of medicine·2025

Same author

Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.

The Journal of investigative dermatology·2024

Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026

Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026

Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026

Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026

Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026

Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

Published on: April 10, 2018

A Dengue Vaccine.

Anna P Durbin¹

¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

|July 2, 2016

Summary

This summary is machine-generated.

Denvaxia is the first licensed vaccine for preventing dengue fever. This live vaccine, administered in three doses annually, can significantly reduce hospitalizations.

More Related Videos

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Related Experiment Videos

Last Updated: Mar 18, 2026

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

Published on: April 10, 2018

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Area of Science:

Vaccinology
Infectious Diseases
Biotechnology

Background:

Dengue fever poses a significant global health burden, necessitating effective prevention strategies.
The development of a dengue vaccine has been a long-standing goal in public health.

Purpose of the Study:

To introduce Denvaxia, the first licensed vaccine for dengue prevention.
To highlight the vaccine's potential impact on public health by reducing hospitalizations.

Main Methods:

Denvaxia is a live vaccine.
It utilizes recombinant DNA technology for its development.
The vaccination schedule involves three doses over one year.

Main Results:

Denvaxia is the first vaccine approved for dengue prevention.
The vaccine has the potential to prevent a substantial number of dengue-related hospitalizations annually.

Conclusions:

Denvaxia represents a significant advancement in the control of dengue fever.
The vaccine's widespread use could lead to a considerable decrease in disease burden.